Jonas Ghouse

Dr. Jonas Ghouse


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JGJonas Ghouse
Jonas Ghouse
VTVinicius Tragante
Vinicius Tragante
GAGustav Ahlberg
Gustav Ahlberg
SRSøren A. Rand
Søren A. Rand
JJJakob B. Jespersen
Jakob B. Jespersen
HBHenning Bundgaard
Henning Bundgaard

17 April 2024 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JGJonas Ghouse
Jonas Ghouse
GSGardar Sveinbjörnsson
Gardar Sveinbjörnsson
MVMarijana Vujkovic
Marijana Vujkovic
ASAnne-Sofie Seidelin
Anne-Sofie Seidelin
HGHelene Gellert-Kristensen
Helene Gellert-Kristensen
SSStefan Stender
Stefan Stender
We report a multi-ancestry genome-wide association study on liver cirrhosis and its associated endophenotypes, alanine aminotransferase (ALT) and γ-glutamyl transferase. Using data from 12 cohorts, including 18,265 cases with cirrhosis, 1,782,047 controls, up to 1 million individuals with liver function tests and a validation cohort of 21,689 cases and 617,729 controls, we identify and validate 14 risk associations for cirrhosis. Many variants are located near genes involved in hepatic lipid metabolism. One of these, PNPLA3 p.Ile148Met, interacts with alcohol intake, obesity and diabetes on the risk of cirrhosis and hepatocellular carcinoma (HCC). We develop a polygenic risk score that associates with the progression from cirrhosis to HCC. By focusing on prioritized genes from common variant analyses, we find that rare coding variants in GPAM associate with lower ALT, supporting GPAM as a potential target for therapeutic inhibition. In conclusion, this study provides insights into the genetic underpinnings of cirrhosis.

20 September 2022 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
AHAnna Helgadottir
Anna Helgadottir
GTGudmar Thorleifsson
Gudmar Thorleifsson
ASAudunn Snaebjarnarson
Audunn Snaebjarnarson
LSLilja Stefansdottir
Lilja Stefansdottir
GSGardar Sveinbjornsson
Gardar Sveinbjornsson
HHHilma Holm
Hilma Holm
The causal contribution of apolipoprotein B (apoB) particles to coronary artery disease (CAD) is established. We examined whether this atherogenic contribution is better reflected by non-high-density lipoprotein cholesterol (non-HDL-C) or apoB particle concentration. We performed Mendelian randomization (MR) analysis using 235 variants as genetic instruments; testing the relationship between their effects on the exposures, non-HDL-C and apoB, and on the outcome CAD using weighted regression. Variant effect estimates on the exposures came from the UK Biobank (N = 376 336) and on the outcome from a meta-analysis of five CAD datasets (187 451 cases and 793 315 controls). Subsequently, we carried out sensitivity and replication analyses. In univariate MR analysis, both exposures associated with CAD (βnon-HDL-C = 0.40, P = 2.8 × 10−48 and βapoB = 0.38, P = 1.3 × 10−44). Adding effects on non-HDL-C into a model that already included those on apoB significantly improved the genetically predicted CAD effects (P = 3.9 × 10−5), while adding apoB into the model including non-HDL-C did not (P = 0.69). Thirty-five per cent (82/235) of the variants used as genetic instruments had discordant effects on the exposures, associating with non-HDL-C/apoB ratio at P < 2.1 × 10−4 (0.05/235). Fifty-one variants associated at genome-wide significance. Many sequence variants have discordant effects on non-HDL-C and apoB. These variants allowed us to show that the causal mechanism underlying the relationship between apolipoprotein B particles and CAD is more associated with non-HDL-C than apoB particle concentration.

18 September 2017 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
JGJonas Ghouse
Jonas Ghouse
MSMorten W. Skov
Morten W. Skov
RBRobert S. Bigseth
Robert S. Bigseth
GAGustav Ahlberg
Gustav Ahlberg
JKJørgen K. Kanters
Jørgen K. Kanters
MOMorten Olesen
Morten Olesen

1 August 2021 in JACC
Verified
Journal Article
Closed access
JGJonas Ghouse
Jonas Ghouse
GAGustav Ahlberg
Gustav Ahlberg
LALaura Andreasen
Laura Andreasen
KBKarina Banasik
Karina Banasik
SBSøren Brunak
Søren Brunak
MOMorten S. Olesen
Morten S. Olesen

8 October 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JGJonas Ghouse
Jonas Ghouse
GAGustav Ahlberg
Gustav Ahlberg
SRSøren Albertsen Rand
Søren Albertsen Rand
MOMorten Salling Olesen
Morten Salling Olesen
BVBjarni Vilhjalmsson
Bjarni Vilhjalmsson
HBHenning Bundgaard
Henning Bundgaard
Lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disease.1 Given the strong genetic influence on Lp(a) concentrations, a single measurement throughout the course of life has been suggested.2 Here, we evaluate the temporal stability of Lp(a) as a function of baseline Lp(a) levels.